Health Information Search Results
Peer Reviewed Scientific Research Reports.
|<< Prev 20 ||Showing 1 to 18 of 18 Matches||Next 20 >>|
1. Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C.
Match Strength: 8.891
Several studies have suggested that lactoferrin administration may decrease the serum level of hepatitis C virus (HCV) RNA in patients with chronic hepatitis C. The aim of the present study was to confirm the efficacy of orally administered bovine lactoferrin (bLF) in patients with chronic hepatitis C. The patients with chronic hepatitis C randomly received either oral bLF at a dose of 1.8 g daily for 12 weeks, or an oral placebo. The primary endpoint was the virologic response, defined as a 50% or greater decrease in serum HCV RNA level at 12 weeks compared with the baseline. The secondary ... Read More »
» Published in Cancer Sci. 2006 Oct;97(10):1105-10.
2. Detection of SEN virus in the general population and different risk groups in Slovakia.
Match Strength: 8.674
Sera of 426 adult persons were examined to assess the prevalence of SEN virus (SENV) infection in Slovakia and to determine the importance of different risk factors for parenteral transmission. SENV prevalence was determined by the PCR method using primers of SENV-D and SENV-H strains. Positive results were found in 10 of 37 patients with acute hepatitis of unknown etiology, 7 of 38 with acute hepatitis B, 17 of 44 with chronic hepatitis B, 29 of 102 with chronic hepatitis C, 36 of 72 hemodialysis patients, 2 of 33 health care workers and 24 of 100 persons from the control group. The highest ... Read More »
» Published in Folia Microbiol (Praha). 2006;51(3):223-8.
3. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Match Strength: 8.233
OBJECTIVE: At present sequential monotherapy for chronic hepatitis B with hepatitis B virus (HBV)-polymerase inhibitors is clinical practice. It is unknown to date whether combination therapy with lamivudine plus tenofovir could be superior to sequential therapy with tenofovir after the occurrence of lamivudine resistance. METHODS: We conducted a multicenter, 1: 2 matched pair analysis comparing patients with HBV/HIV-coinfection starting an antiretroviral regimen including tenofovir plus lamivudine with patients who had highly replicative, lamivudine resistant HBe-antigen positive chronic ... Read More »
» Published in AIDS. 2006 Oct 3;20(15):1951-4.
4. Phenotypic and functional status of intrahepatic T cells in chronic hepatitis C.
Match Strength: 8.025
Polychromatic flow-cytometric assays were used to analyze paired intrahepatic and peripheral lymphocyte samples from 37 patients with chronic hepatitis C. Compared with peripheral cells, intrahepatic T cells were selectively enriched with CD45RO+ memory T cells but had a lower percentage of CD4+ T cells expressing the differentiation markers CD27 and CD28. The percentage of intrahepatic CD45RO+ and CD28+ T cells correlated with the degree of liver inflammation, which suggests that memory T cells at relatively early stages of differentiation are directly involved in liver inflammation. Despite ... Read More »
» Published in J Infect Dis. 2006 Oct 15;194(8):1068-77. Epub 2006 Sep 15.
5. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations.
Match Strength: 7.745
OBJECTIVES: To assess the efficacy of sequential treatment with lamivudine and interferon-alpha monotherapies in Chinese patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. METHODS: One hundred and sixty-two patients with HBeAg-negative chronic hepatitis B were included in this study. Ninety-eight were treated with lamivudine alone (100 mg per day) for 48 weeks (group B). Sixty-four were treated with lamivudine alone (100 mg per day) for 20 weeks, then combined with interferon-alpha-2b (5 million units three times per week) for 4 weeks and then treated for another 24 ... Read More »
» Published in J Antimicrob Chemother. 2006 Nov;58(5):1031-5. Epub 2006 Sep 19.
6. Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment.
Match Strength: 7.605
OBJECTIVES: To evaluate the alterations of serum procalcitonin (PCT) levels in patients with chronic hepatitis C during pegylated interferon-alpha (PEG-IFNa) plus ribavirin (RIB) treatment and to correlate them with clinical and virological outcomes. STUDY DESIGN: Fifty-two consecutive patients (29 males, age=41.2+/-14.7 years) with chronic HCV-related liver disease (six cirrhotics) were evaluated for PCT levels at baseline and during the treatment course (at week 12, 24, 48 and 72) with PEG-IFNa plus RIB. Sustained virological response (SVR) was confirmed by undetectable serum HCV-RNA at the ... Read More »
» Published in J Clin Virol. 2006 Dec;37(4):329-31. Epub 2006 Sep 25.
7. The status of liver transplantation for hepatitis C.
Match Strength: 7.416
The hepatitis C virus (HCV) infects 3% of the world's population, or approximately 170 million people. Most of those acutely infected progress to chronic infection and are unresponsive to existing antiviral treatment. Over a 20-year period, chronic HCV infection leads to cirrhosis and the sequelae of end-stage liver disease, including hepatic encephalopathy, ascites, variceal haemorrhage and hepatocellular carcinoma. Orthotopic liver transplantation (OLT) is the optimal treatment for decompensated HCV cirrhosis, but is limited by organ availability and universal graft reinfection. This review ... Read More »
» Published in Expert Opin Biol Ther. 2006 Oct;6(10):993-1002.
8. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.
Match Strength: 6.459
The results of antiviral therapy for hepatitis C virus (HCV) have improved recently with the use of pegylated interferon (PEG-IFN)/ribavirin (RBV) combination therapy. At this point, most patients with chronic HCV remain untreated. Thus, it is anticipated that therapy will be more appealing and prescribed more broadly than in the past, including in patients considered marginal. AIM: To examine the effects of PEG-IFN-based antiviral therapy in elderly patients with chronic HCV. METHODS: The charts of patients treated with chronic HCV were reviewed. Patients were defined as elderly if they were ... Read More »
» Published in Can J Gastroenterol. 2006 Sep;20(9):589-92.
9. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Match Strength: 6.277
The immune suppression caused by HIV infection accelerates the course of liver disease caused by chronic hepatitis B virus (HBV) infection. We assessed the outcome of HIV/HBV-coinfected patients exposed to highly active antiretroviral therapy (HAART) including anti-HBV active drugs. Baseline and follow-up plasma HBVDNA and HIV-RNA levels, HBV serological markers, and CD4 counts were longitudinally evaluated in all HBsAg(+) individuals with HIV infection on regular follow-up at an urban HIV reference clinic. Out of 79 HBsAg(+) chronic carriers identified, 39 (50%) were HBeAg(+). Lamivudine (3TC ... Read More »
» Published in AIDS Res Hum Retroviruses. 2006 Sep;22(9):842-8.
10. Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B.
Match Strength: 6.240
OBJECTIVE: To determine the prevalence of precore and core promoter (CP) mutations before, at and after HBeAg seroclearance in Chinese patients. METHODS: Precore and CP mutations were determined in 93 patients with chronic hepatitis B 12-24months before, at and 12months after the time of HBeAg seroclearance. RESULTS: No significant changes were found in the prevalence of precore or CP mutations before, at and after HBeAg seroclearance. Seven patients (7.8%) had HBeAg seroreversion within 1year of HBeAg seroclearance. There was no significant difference in the prevalence of precore and CP ... Read More »
» Published in J Infect. 2006 Sep 21;
11. Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C.
Match Strength: 6.220
The aim of the 18 months follow up study was to assess the frequency of anemia during IFN/RBV therapy in patients with chronic hepatitis C; to manage anemia either with recombinant human erythropoietin (rHuEPO)--epoetin alpha or with RBV dose reduction and to compare the rate of SVR in patients with RBV dose reduction and with administration of epoetin alpha. Study enrolled 61 patients with chronic active hepatitis C aged 33-61 years. All patients had HCV genotype 1b. Out of them 41 were male and 20 female. Anemia (Hb <10 or >2 g/dL Hgb drop from baseline) developed in 41 patients out of ... Read More »
» Published in Georgian Med News. 2006 Aug;(137):62-5.
12. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein.
Match Strength: 5.514
The progression of chronic hepatitis B (CHB) is related to fibrosis and to the emergence of intrahepatic anomalous vascular structures. Hepatitis B virus (HBV) X protein transactivator (HBx) may play a significant role in both processes. To analyze how HBV induces vascular growth and remodeling in vivo, we assessed the expression of angiopoietin-2 (Ang2) in liver biopsies from CHB patients by reverse transcriptase-polymerase chain reaction, Western blotting, and immunohistochemistry because of the relevant role of Ang2 in vascular development, remodeling, and tumor promotion. In addition, we ... Read More »
» Published in Am J Pathol. 2006 Oct;169(4):1215-22.
13. Liver steatosis in hepatitis C positive hemodialysis patients and factors affecting IFN-2a treatment.
Match Strength: 5.033
OBJECTIVE: Hepatitis C virus (HCV) infection is endemic among hemodialysis (HD) patients. It is well known that HCV causes approximately 50% of hepatosteatosis in patients with normal renal function and that this rate is higher in patients infected with genotype 3. The aim of this study was to investigate the rate of steatosis, the regression in steatosis with interferon (IFN) treatment and factors affecting IFN treatment in hemodialysis patients with chronic hepatitis C (CHC). MATERIAL AND METHODS: Thirty-seven HD patients with CHC were included in the study. All patients received ... Read More »
» Published in Scand J Gastroenterol. 2006 Oct;41(10):1235-41.
14. Peripheral insulin resistance during treatment of chronic hepatitis C with peguilated interferon plus ribavirin.
Match Strength: 4.952
Patients with hepatitis C virus (HCV) infection present higher risk of developing type-2 diabetes mellitus (DM). However, the mechanism of this association and the role of antiviral treatment are still unclear. The objective of this study was to investigate the relationship between the use of peguilated interferon and the development of insulin resistance (IR) in these patients. METHODS: HOMA index was evaluated in 30 HCV-infected patients just before and during the first 6 months of treatment with peguilated interferon plus ribavirin. Anthropometrical parameters and glucose/cholesterol ... Read More »
» Published in J Med Virol. 2006 Nov;78(11):1406-10.
15. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients.
Match Strength: 4.634
Systemic B-cell depletion and clinical remission of the systemic effects of cryoglobulins have been achieved in hepatitis C virus-positive immunocompetent patients with rituximab, a human/mouse chimeric monoclonal antibody that specifically reacts with the CD20 antigen. Thus, this provides a rationale for the use of rituximab for type III cryoglobulin-related graft dysfunction in renal-transplant patients. Seven patients, of whom five were hepatitis C positive, developed renal function impairment long after transplantation, as well as de novo nephrotic syndrome (n = 5), severe hypertension (n ... Read More »
» Published in Transplant Proc. 2006 Sep;38(7):2308-10.
16. Association between calciphylaxis and inflammation in two patients on chronic dialysis.
Match Strength: 4.261
The pathogenesis of calciphylaxis, which has a rising incidence in the chronic dialysis population and a high mortality rate, is poorly understood. Abnormalities in the calcium-phosphorus-parathyroid axis are clinically related to calciphylaxis, but alone, they cannot explain this condition. Here, we present two patients who had chronic inflammatory conditions and hyperparathyroidism and who developed calciphylaxis. A 41-year-old white woman on hemodialysis following scleroderma, hepatitis C, liver transplant, and failed kidney transplant, developed progressive ulcerative lower extremity ... Read More »
» Published in Adv Perit Dial. 2006;22:171-4.
17. Dynamics of a hepatitis B virus e antigen minus population ascribed to genotype F during the course of a chronic infection despite the presence of anti-HBs antibodies.
Match Strength: 3.858
The in vivo evolution of genotype F HBV variants was recorded in a chronically infected patient throughout a 3-year observation period. Fluctuating levels of HBs Ag and anti-HBs antibodies were recorded, both of them cocirculating in peripheral blood samples at given times. Fifty S gene derived clones were sequenced and phylogenetically analyzed. As expected, some amino acid replacements within the S ORF were also observed within the P ORF while others were silent for the former. Such change was statistically significant for both S and P overlapping genes, which clearly indicates the ... Read More »
» Published in Virus Res. 2007 Jan;123(1):72-85. Epub 2006 Sep 18.
18. Anti-CCP2 positivity in non-ra disease samples: citrulline-dependent or not?
Match Strength: 3.164
OBJECTIVES: Antibodies directed against citrullinated proteins (e.g. anti-CCP) have excellent diagnostic and good prognostic potential for rheumatoid arthritis (RA). Type 1 autoimmune hepatitis (AIH-1) is a chronic liver disease characterized by a variety of serum autoantibodies. Recently, in a large group of AIH- 1 patients without clear RA overlap, a relatively high percentage (9%) of anti-CCP2 positivity was scored. Our aim was to characterize the citrulline-dependence of the observed anti-CCP2 positivity in AIH-1 sera as well as in other groups of non-RA patients (mainly rheumatic diseases ... Read More »
» Published in Ann Rheum Dis. 2006 Sep 19;
|<< Prev 20 ||Showing results 1 to 18 of 18||Next 20 >>|
* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.